Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank Joseph Schmeltz for performing the database search query.

Disclosure statement

The authors declare no competing financial interests. Disclosures of the contributing authors include: Dr. Alina Markova sits on the advisory board for Alira Health, Blueprint Medicines, Janssen, and Protagonist therapeutics, has received research funding from Incyte Corporation and Amryt Pharma, and royalties from UpToDate. Dr. Mailankody has received consulting fees from Evicore, Legend Biotech, and honoraria from Plexus Education and Physician Education Resource. Memorial Sloan Kettering receives research funding from National Cancer Institute, Allogene Therapeutics, Takeda Oncology, Bristol Myers Squibb, Juno Therapeutics, Janssen Oncology, and Fate Therapeutics for research conducted by Dr. Mailankody. Urvi Shah has received research support from Celgene/Bristol Myers Squibb and Janssen paid to the institution. Urvi Shah is funded by the NCI MSK Paul Calabresi Career Development Award for Clinical Oncology (K12CA184746). Heather Landau, MD has received research funding from Takeda paid to the MSK. She also has served on advisory boards for Takeda, Caelum pharmaceuticals, Janssen, Celgene/Bristol Myers Squibb, Sanofi/Genzyme, Pfizer and Karyopharm.

Additional information

Funding

This study was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.